Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals
Background Idarucizumab, a monoclonal antibody fragment that reverses the anticoagulant effect of dabigatran, was approved for use in Canada in 2016. Objective Our objective was to assess the safe...
onlinelibrary.wiley.com